Tenax Therapeutics: Cantor Sees 2x–3x Upside as First PH-HFpEF Drug Nears Pivotal Data

Cantor Fitzgerald initiates Overweight on Tenax Therapeutics with $35 target. Under-the-radar biotech nears Q3 2026 Phase 3 readout for potential first PH-HFpEF therapy — high-risk, high-reward setup.